x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Prova Education

Prova Education designs educational programs that address a broad spectrum of gaps in awareness, attitudes, skills, and competencies related to guideline-based care and evolving disease management options. Its mission is to serve as an innovative and relevant resource for clinical content that promotes change in practice and patient outcomes.

science & medicine medicine

All Episodes

00:00:00

Cell and Gene Therapies for Sickle Cell Disease

Prova Education ·

2023/08/14

Guest: Biree Andemariam, MD Sickle cell disease (SCD) imposes a substantial and life-long healthcare burden on patients coupled with psychosocial and financial burdens on patients and their caregivers. Current treatment approaches, while beneficial, are not curative, and often fail to overcome painful and at times life-threatening crises. While dramatic changes to treatment are on the horizon, their wide availability and long-term outcomes remain unknown. Join Drs. Andemariam and

en

00:00:00

Improving Communication Across Care Settings

Prova Education ·

2023/08/14

Guest: Biree Andemariam, MD Guest: Caroline Freiermuth, MD Sickle cell disease (SCD) imposes a substantial and life-long healthcare burden on patients coupled with psychosocial and financial burdens on patients and their caregivers. Current treatment approaches, while beneficial, are not curative, and often fail to overcome painful and at times life-threatening crises. While dramatic changes to treatment are on the horizon, their wide availability and long-term outcomes remain

en

00:00:00

Implementing the Sickle Cell Treatment Regimen

Prova Education ·

2023/08/14

Guest: Biree Andemariam, MD Guest: Caroline Freiermuth, MD Sickle cell disease (SCD) imposes a substantial and life-long healthcare burden on patients coupled with psychosocial and financial burdens on patients and their caregivers. Current treatment approaches, while beneficial, are not curative, and often fail to overcome painful and at times life-threatening crises. While dramatic changes to treatment are on the horizon, their wide availability and long-term outcomes remain

en

00:00:00

Why Do We Need New Therapies for Sickle Cell Disease?

Prova Education ·

2023/08/14

Guest: Biree Andemariam, MD Guest: Caroline Freiermuth, MD Sickle cell disease (SCD) imposes a substantial and life-long healthcare burden on patients coupled with psychosocial and financial burdens on patients and their caregivers. Current treatment approaches, while beneficial, are not curative, and often fail to overcome painful and at times life-threatening crises. While dramatic changes to treatment are on the horizon, their wide availability and long-term outcomes remain

en

00:00:00

The Burden of Sickle Cell Disease for Patients and...

Prova Education ·

2023/08/14

Guest: Biree Andemariam, MD Sickle cell disease (SCD) imposes a substantial and life-long healthcare burden on patients coupled with psychosocial and financial burdens on patients and their caregivers. Current treatment approaches, while beneficial, are not curative, and often fail to overcome painful and at times life-threatening crises. While dramatic changes to treatment are on the horizon, their wide availability and long-term outcomes remain unknown. Join Drs. Andemariam and

en

00:00:00

Making the Transition: Managing Patients with Sickle...

Prova Education ·

2023/08/14

Guest: Biree Andemariam, MD Sickle cell disease (SCD) imposes a substantial and life-long healthcare burden on patients coupled with psychosocial and financial burdens on patients and their caregivers. Current treatment approaches, while beneficial, are not curative, and often fail to overcome painful and at times life-threatening crises. While dramatic changes to treatment are on the horizon, their wide availability and long-term outcomes remain unknown. Join Drs. Andemariam and

en

00:00:00

Let’s Discuss Transplantation

Prova Education ·

2023/08/14

Guest: Biree Andemariam, MD Sickle cell disease (SCD) imposes a substantial and life-long healthcare burden on patients coupled with psychosocial and financial burdens on patients and their caregivers. Current treatment approaches, while beneficial, are not curative, and often fail to overcome painful and at times life-threatening crises. While dramatic changes to treatment are on the horizon, their wide availability and long-term outcomes remain unknown. Join Drs. Andemariam and

en

00:00:00

Preventative Management of Sickle Cell Disease...

Prova Education ·

2023/08/14

Guest: Biree Andemariam, MD Guest: Caroline Freiermuth, MD Sickle cell disease (SCD) imposes a substantial and life-long healthcare burden on patients coupled with psychosocial and financial burdens on patients and their caregivers. Current treatment approaches, while beneficial, are not curative, and often fail to overcome painful and at times life-threatening crises. While dramatic changes to treatment are on the horizon, their wide availability and long-term outcomes remain

en

00:00:00

Diverse Manifestations of Sickle Cell Disease

Prova Education ·

2023/08/14

Guest: Biree Andemariam, MD Guest: Caroline Freiermuth, MD Sickle cell disease (SCD) imposes a substantial and life-long healthcare burden on patients coupled with psychosocial and financial burdens on patients and their caregivers. Current treatment approaches, while beneficial, are not curative, and often fail to overcome painful and at times life-threatening crises. While dramatic changes to treatment are on the horizon, their wide availability and long-term outcomes remain

en

00:00:00

A Quick Look at Standard Treatments for Sickle Cell...

Prova Education ·

2023/08/14

Guest: Biree Andemariam, MD Guest: Caroline Freiermuth, MD Sickle cell disease (SCD) imposes a substantial and life-long healthcare burden on patients coupled with psychosocial and financial burdens on patients and their caregivers. Current treatment approaches, while beneficial, are not curative, and often fail to overcome painful and at times life-threatening crises. While dramatic changes to treatment are on the horizon, their wide availability and long-term outcomes remain

en

00:00:00

The HPV Vaccine Announcement for Children and...

Prova Education ·

2023/07/27

Guest: Kenneth Alexander, MD, PhD Guest: Noel T. Brewer, PhD Healthcare providers face challenges in promoting HPV vaccination, which is now recommended for children at age 9. The good news is that there are scientifically validated, effective methods for promoting HPV vaccination. Tune in to learn more about the 3-step Announcement Approach and discover strategies to address parents' hesitation and optimize cancer prevention.

en

00:00:00

Keeping Pace in Hematologic Malignancies: 2023...

Prova Education ·

2023/07/24

Host: Harry Paul Erba, MD, PhD Guest: Courtney DiNardo, MD Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Immuno-oncologic agents have changed the treatment landscape for non-small cell lung cancer. Listen as Drs. Harry Erba and Courtney DiNardo discuss advances in molecular profiling and classification of AML, as well as the newest approved treatments.

en

00:00:00

Delivering Change: Mechanisms to Address Racial...

Prova Education ·

2023/07/21

Host: Joseph Mikhael, MD Guest: Monique Hartley-Brown, MD Guest: Brandon Blue, MD Multiple myeloma (MM) is the most common hematologic malignancy among African Americans, so it’s important that healthcare providers are aware of the disparities in the treatment provided to Black patients and White patients with MM. Listen in as Drs. Joseph Mikhael, Brandon Blue, and Monique Hartley-Brown discuss strategies to manage racial disparities and begin closing these gaps to ensure all

en

00:00:00

In the Medical Spotlight: Antibody-Drug Conjugates in...

Prova Education ·

2023/07/20

Host: John L. Marshall, MD Gastric and gastroesophageal junction cancers are the third most common cause of cancer deaths globally. In this Chairman’s Perspective, Dr. John Marshall breaks down the latest data from the 2023 World Congress on GI Cancer in Barcelona, Spain, so you can more effectively treat your patients.

en

00:00:00

Patient Selection for ADCs in First-Line DLBCL

Prova Education ·

2023/07/15

Host: John P. Leonard, MD Guest: Sarah Rutherford, MD This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma. On May 19, 2023, the FDA granted accelerated approval to epcoritamab-bysp (Epkinly) for relapsed or refractory diffuse large

en

00:00:00

First-Line Treatment of Adults with Classical Hodgkin...

Prova Education ·

2023/07/15

Host: Alex Herrera, MD Guest: Alison J. Moskowitz, MD This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma. On May 19, 2023, the FDA granted accelerated approval to epcoritamab-bysp (Epkinly) for relapsed or refractory diffuse large

en

00:00:00

Individualizing Frontline Treatment

Prova Education ·

2023/07/15

Host: Alex Herrera, MD Guest: Alison J. Moskowitz, MD This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma. On May 19, 2023, the FDA granted accelerated approval to epcoritamab-bysp (Epkinly) for relapsed or refractory diffuse large

en

00:00:00

Clinical Implications of Bispecific Antibodies and...

Prova Education ·

2023/07/15

Host: Kami Maddocks, MD Guest: Matthew J. Matasar, MD This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma. On May 19, 2023, the FDA granted accelerated approval to epcoritamab-bysp (Epkinly) for relapsed or refractory diffuse large

en

00:00:00

Application of Data from the ECHELON-1 Trial

Prova Education ·

2023/07/15

Host: Alison J. Moskowitz, MD Guest: Alex Herrera, MD This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma. On May 19, 2023, the FDA granted accelerated approval to epcoritamab-bysp (Epkinly) for relapsed or refractory diffuse large

en

00:00:00

Bispecific Antibodies in FL

Prova Education ·

2023/07/15

Host: Kami Maddocks, MD Guest: Matthew J. Matasar, MD This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma. On May 19, 2023, the FDA granted accelerated approval to epcoritamab-bysp (Epkinly) for relapsed or refractory diffuse large

en

134 results

Similar Podcasts

科学史评话最新专辑

科学史评话

Hablando con Científicos - Cienciaes.com

cienciaes.com

天方烨谈

基因频道

The Permaculture Podcast

Scott Mann

汪诘：科学有故事（主打）

科学有故事